Returns At Calumet (NASDAQ:CLMT) Are On The Way Up
Goldman Sachs Maintains Calumet Partners(CLMT.US) With Buy Rating, Raises Target Price to $22
Goldman Sachs analyst Neil Mehta maintains $Calumet Partners(CLMT.US)$ with a buy rating, and adjusts the target price from $17 to $22.According to TipRanks data, the analyst has a success rate of 61.
Calumet Up Over 17%, on Track for Highest Close Since December 2015 -- Data Talk
Zoom Video Posts Strong Q2 Results, Joins Peloton Interactive, Opera And Other Big Stocks Moving Higher On Thursday
Calumet to Attend Barclays 38th Annual CEO Energy-Power Conference
Calumet, Inc. (NASDAQ:CLMT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
HC Wainwright & Co. Reiterates Buy on Calumet, Maintains $25 Price Target
Calumet Specialty Prods Is Maintained at Buy by TD Cowen
Express News | Calumet Inc : TD Cowen Cuts Target Price to $18 From $20
Calumet Partners | 10-Q: Q2 2024 Earnings Report
Calumet Specialty Prods Shares Are Trading Higher Following a Q2 Revenue Beat.
Calumet Specialty's Q2 Net Loss Widens, Revenue Rises
Express News | Calumet Specialty Products Partners LP- Qtrly Shr Loss $0.48
Calumet Specialty Prods Q2 2024 GAAP EPS $(0.48) Misses $(0.46) Estimate, Sales $1.133B Beat $981.510M Estimate
Express News | Calumet Reports Second Quarter 2024 Results
Calumet 2Q Sales $1.13B >CLMT
Here Is the Next Potential Market Catalyst
Calumet Specialty Prods Is Maintained at Buy by Goldman Sachs
Calumet Specialty Prods Price Target Cut to $15.00/Share From $17.00 by Goldman Sachs
Calumet Analyst Ratings